David J. Chung
YOU?
Author Swipe
View article: Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial
Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma – final results from a randomized investigator-initiated trial Open
Introduction Lenalidomide (len) is the standard maintenance therapy in multiple myeloma (MM) due to its proven survival benefits. Daratumumab (dara) single-agent maintenance when compared to observation has shown improved PFS. This investi…
View article: Protocol for the development of NHMRC-endorsed guidelines for extracorporeal membrane oxygenation using GRADE methodology
Protocol for the development of NHMRC-endorsed guidelines for extracorporeal membrane oxygenation using GRADE methodology Open
The guideline will be published in peer-reviewed journals and summaries will be provided to end-users via the GRADEpro GDT application.
View article: Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)
Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM) Open
Introduction/Background: Chimeric antigen receptor (CAR)-modified T cells targeting BCMA have shown high response rates and durable remissions in patients with relapsed or refractory multiple myeloma (RRMM). Since this innovative therapy l…
View article: Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma
Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma Open
Introduction: Talquetamab, a G protein-coupled receptor, class C group 5 member D (GPRC5D)-directed bispecific antibody (BsAb), was approved in August 2023 for patients with relapsed/refractory multiple myeloma (RRMM) who have received ≥4 …
View article: Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma Open
Introduction: Infections cause significant morbidity among relapsed refractory multiple myeloma (RRMM) patients receiving chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs). Real-world infection data in patien…
View article: Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies
Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies Open
Introduction/Background: Chimeric antigen receptor (CAR)-T cell and bispecific antibody (BsAb) therapies demonstrated high response rates in relapsed/refractory multiple myeloma (RRMM), yet patients often experience significant toxicities.…
View article: Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment
Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment Open
Backgroun d: Identifying novel antigenic targets for immune-based therapy in Multiple Myeloma (MM) is a critical area of investigation. The BMT CTN 1401 (NCT02728102), a national randomized trial evaluating dendritic cell (DC)/MM fusion ce…
View article: Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial
Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial Open
Introduction Maintenance strategies in newly diagnosed multiple myeloma (NDMM) are evolving given the availability of novel single agent and combination strategies aimed at improving progression free survival (PFS) without worsening qualit…
View article: A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma
A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma Open
Introduction Poor diet quality, elevated body mass index (BMI), insulin resistance, microbiome dysbiosis, inflammation as well as immune dysfunction have all been implicated in progression from monoclonal gammopathy of undetermined signifi…
View article: Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
Impact of Daratumumab Refractoriness on Clinical Outcomes Following CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma Open
Introduction: Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) are two chimeric antigen receptor (CAR) T-cell products targeting B-cell maturation antigen (BCMA) that have recently been approved for the treatment …
View article: Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network
Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network Open
Background: Contemporary questions about treatment and outcomes of patients (pts) living with multiple myeloma (MM) demand efficient and timely evidence generation methods, where real-world/ everyday practice data can play an important rol…
View article: Evaluating serum free light chain ratio as a biomarker in multiple myeloma
Evaluating serum free light chain ratio as a biomarker in multiple myeloma Open
Not available.
View article: Data from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Data from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Purpose: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating MM-reactive lymphocytes and consolidation of clinical response following autologous hematopoietic cell transp…
View article: Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Study representation of underserved communities
View article: Figure S1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Figure S1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Supplemental Figure 1: (A) Progression Free Survival Kaplan Meier Curve. (B) Overall Survival Kaplan Meier Curve.
View article: Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Study Representativeness Table1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Study representation of underserved communities
View article: Figure S1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma
Figure S1 from Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma Open
Supplemental Figure 1: (A) Progression Free Survival Kaplan Meier Curve. (B) Overall Survival Kaplan Meier Curve.
View article: Regulation of the hematopoietic stem cell pool by C-Kit–associated trogocytosis
Regulation of the hematopoietic stem cell pool by C-Kit–associated trogocytosis Open
Hematopoietic stem cells (HSCs) are routinely mobilized from the bone marrow (BM) to the blood circulation for clinical transplantation. However, the precise mechanisms by which individual stem cells exit the marrow are not understood. Thi…
View article: Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Table S1-S4
View article: Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Figure S1. Volcano plot showing the difference in the relative abundance of butyrate producers between sustained MRD negative and MRD positive/non-sustained MRD negative.
View article: Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary fig 1 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Figure S1. Volcano plot showing the difference in the relative abundance of butyrate producers between sustained MRD negative and MRD positive/non-sustained MRD negative.
View article: Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Supplementary Data TS1-4 from Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets Open
Supplementary Table S1-S4
View article: Patients’ Perceptions, Experiences, and Feedback on a Pilot Plant-Based Dietary Intervention: A Qualitative Survey
Patients’ Perceptions, Experiences, and Feedback on a Pilot Plant-Based Dietary Intervention: A Qualitative Survey Open
Objectives: Providing patient-centered care for those undergoing a dietary intervention is critical in improving outcomes. Our objectives were to understand the perception, experiences, and post-intervention plans of those who completed ou…
View article: Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma
Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma Open
Lenalidomide maintenance is associated with a significantly improved progression-free in patients with newly diagnosed multiple myeloma. Maintenance with lenalidomide is generally well tolerated; however, lenalidomide associated diarrhea i…
View article: Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma Open
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-ta…